Kepler upgrades Stratec to 'buy' on projected demand recovery

Stratec SE

25/06/2025 09:55

** Kepler upgrades the German biomedical systems manufacturer Stratec SBSG.DE to "buy" from "hold", as it expects demand to recover

** The broker points to a slump in demand since the Covid pandemic, during which the market for molecular diagnostics was saturated

** The stock value has dropped 83 percent from its peak value in 2021, Kepler adds

** However, the analyst says that "the business is clearly viable", "the recovery of industrial demand is a question of time" and "leverage is not a concern"

** Therefore, Kepler views Stratec's stock as undervalued

** Stratec shares are up 4.65%, making Stratec on of the top gainers on the .SDAXI index

(Reporting by Simon Ferdinand Eibach)

((Simonferdinand.eibach@thomsonreuters.com))